

- A<sup>1</sup>
- (a) providing at least one rAAV virion, said at least one rAAV virion comprising a vector further comprising a heterologous nucleic acid sequence, which sequence results in a therapeutic effect when delivered to said human; and
  - (b) delivering said rAAV virions to said human under conditions wherein said heterologous nucleic acid sequence is expressed at a therapeutic level, wherein said human has preexisting anti-AAV antibodies.
- 

A<sup>2</sup>

13. (Amended) A method of treating hemophilia in a human, comprising:

- (a) providing at least one recombinant adeno-associated virus (rAAV) virion, said rAAV virion comprising a vector further comprising a heterologous nucleic acid sequence further comprising a gene encoding a blood coagulation factor; and
  - (b) delivering said rAAV virions to said human under conditions wherein said gene is expressed at a therapeutic level, wherein said human has preexisting anti AAV antibodies.
- 

Please cancel claim 3 without ~~prejudice~~ and without disclaimer.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version with markings to show changes made.**"

**Remarks**

Claims 1 and 13 have been amended herein to recite the subject invention with greater particularity. Specifically, minor wording modifications have been made to claims 1 and 13 and recitations from canceled claim 3 have been incorporated into claim 1. Cancellation of claim 3 is without prejudice, without intent to abandon any originally claimed subject matter, and without intent to acquiesce in any rejection of record. Applicants reserve the right to bring the canceled claims again in a related application.